Global Assets Advisory LLC Trims Holdings in Abbott Laboratories $ABT

Global Assets Advisory LLC reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 40.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,316 shares of the healthcare product maker’s stock after selling 3,662 shares during the quarter. Global Assets Advisory LLC’s holdings in Abbott Laboratories were worth $723,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ABT. Brighton Jones LLC grew its position in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares in the last quarter. Congress Asset Management Co. grew its holdings in Abbott Laboratories by 6.3% during the 1st quarter. Congress Asset Management Co. now owns 3,529 shares of the healthcare product maker’s stock worth $468,000 after acquiring an additional 210 shares in the last quarter. Sivia Capital Partners LLC increased its position in Abbott Laboratories by 4.1% during the 1st quarter. Sivia Capital Partners LLC now owns 4,606 shares of the healthcare product maker’s stock valued at $611,000 after purchasing an additional 180 shares during the period. UMB Bank n.a. raised its holdings in shares of Abbott Laboratories by 20.1% in the 1st quarter. UMB Bank n.a. now owns 307,903 shares of the healthcare product maker’s stock valued at $40,843,000 after purchasing an additional 51,511 shares in the last quarter. Finally, Wedmont Private Capital lifted its position in shares of Abbott Laboratories by 51.9% in the 1st quarter. Wedmont Private Capital now owns 29,190 shares of the healthcare product maker’s stock worth $3,704,000 after purchasing an additional 9,976 shares during the period. Institutional investors own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $134.49 on Monday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a market capitalization of $234.07 billion, a price-to-earnings ratio of 16.85, a PEG ratio of 2.55 and a beta of 0.69. The stock’s 50-day simple moving average is $131.94 and its 200-day simple moving average is $131.39.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same period last year, the business earned $1.14 EPS. Abbott Laboratories’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ABT. BTIG Research reduced their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, July 18th. Weiss Ratings reissued a “buy (b)” rating on shares of Abbott Laboratories in a research report on Saturday, September 27th. Royal Bank Of Canada raised their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Tuesday, July 15th. Leerink Partners assumed coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They issued a “market perform” rating and a $143.00 target price for the company. Finally, Mizuho raised their price target on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, July 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $145.39.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.